Applications
AAV
AAV gene therapies hold transformative promise, but translational failure remains the industry's greatest obstacle. Species differences in receptor expression, unpredictable hepatotropism across serotypes, and the absence of physiologically relevant in vitro tools have left developers relying on costly NHP studies that too often fail to predict human outcomes
The Javelin platform integrates primary human hepatocytes and non-parenchymal cells in a native-like D tissue architecture delivering a high-fidelity model that recapitulates AAV behavior within a human biological context, enabling preclinical selection of the most e cacious and least hepatotoxic serotype candidate before first-in-human studies.
ONT PKPD
AAV gene therapies hold transformative promise, but translational failure remains the industry's greatest obstacle. Species differences in receptor expression, unpredictable hepatotropism across serotypes, and the absence of physiologically relevant in vitro tools have left developers relying on costly NHP studies that too often fail to predict human outcomes
The Javelin platform integrates primary human hepatocytes and non-parenchymal cells in a native-like D tissue architecture delivering a high-fidelity model that recapitulates AAV behavior within a human biological context, enabling preclinical selection of the most e cacious and least hepatotoxic serotype candidate before first-in-human studies.